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Background. Clinical short-term risk stratiﬁcation is a recommended approach in patients with chest pain and possible acute
myocardial infarction (AMI) to further improve high safety of biomarker-based rule-out algorithms. The study aim was to
assess clinical performance of baseline concentrations of high-sensitivity cardiac troponin T (hs-TnT) and copeptin and the
modiﬁed HEART score (mHS) in early presenters to the emergency department with chest pain. Methods. This cohort
study included patients with chest pain with onset maximum of 6 h before admission and no persistent ST-segment
elevation on electrocardiogram. hs-TnT, copeptin, and the mHS were assessed from admission data. The diagnostic and
prognostic value for three baseline rule-out algorithms: (1) single hs-TnT< 14 ng/l, (2) hs-TnT< 14 ng/l/mHS≤ 3, and (3)
hs-TnT< 14 ng/l/mHS≤ 3/copeptin< 17.4 pmol/l, was assessed with sensitivity and negative predictive value. Primary
diagnostic endpoint was the diagnosis of AMI. Prognostic endpoint was death and/or AMI within 30 days. Results. Among
154 enrolled patients, 44 (29%) were classiﬁed as low-risk according to the mHS; AMI was diagnosed in 105 patients
(68%). For ruling out AMI, the highest sensitivity and NPV from all studied algorithms were observed for hs-TnT/mHS/
copeptin (100%, 95% CI 96.6–100, and 100%, 95% CI 75.3–100). At 30 days, the highest event-free survival was achieved
in patients stratiﬁed with hs-TnT/mHS/copeptin algorithm (100%) with 100% (95% CI 75.3–100) NPV and 100% (95% CI
96.6–100) sensitivity. Conclusions. The combination of baseline hs-TnT, copeptin, and the mHS has an excellent sensitivity
and NPV for short-term risk stratiﬁcation. Such approach might improve the triage system in emergency departments and
be a bridge for inclusion to serial blood sampling algorithms.
1. Introduction
The quality of the management of patients with acute chest
pain in the emergency department is constantly improving;
however, high safety is achieved at the expense of eﬃcacy.
High-sensitivity cardiac troponin (hs-Tn) has been shown
to carry high diagnostic value in this setting [1–6]. Serial
sampling in short time intervals has been studied and vali-
dated to increase the safety and eﬃcacy of early discharge
without the need for further testing [1, 7–10]. Copeptin and
clinical scores were tested and are recommended to further
increase high sensitivity of hs-Tn regarding diagnostic and
prognostic evaluation [11–16]. From the variety of risk
scores, the HEART score combines the most common char-
acteristics used for routine clinical evaluation and assessment
of the probability of cardiac origin of chest pain and acute
coronary syndrome. Easy to assess at bedside in baseline
examination, the HEART score improved the performance
of standard cardiac troponin; however, high safety achieved
with such combination was balanced by time delay to serial
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measurements of biomarkers [11]. Originally composed of
history, electrocardiographic ﬁndings, age, risk factors, and
standard markers of cardiac injury, the HEART score was
modiﬁed by using high-sensitive troponin assays. Recent
studies controvert the value from assessment of the modi-
ﬁed HEART score (mHS) in the era of hs-Tn [17]. To
date, there is no data reporting on safety of a multimarker
strategy and the HEART score at baseline and after intro-
duction of high-sensitivity assays. We therefore aimed to
assess the clinical performance of the mHS with baseline
concentrations of hs-Tn and copeptin in early presenters to
the emergency department with chest pain and suspected
acute coronary syndrome.
2. Materials and Methods
2.1. Study Design. This is a cohort, cross-sectional study,
primary designed to evaluate the role of copeptin in rapid
evaluation of patients with acute chest pain in the emergency
department (COPeptin for Acute Coronary Syndrome/
COPACS/study).
Details on the design and the chart of the study were
widely described previously [9]. In brief, consecutive patients
presenting to the emergency department of the 2nd Depart-
ment of Cardiology, Zabrze, Medical University of Silesia,
Katowice, Poland, were enrolled. Inclusion criteria were chest
pain of a minimum of 5-minute duration with beginning
during the last 6 hours. Patients were excluded in the pres-
ence of persistent ST-segment elevation in an electrocardio-
gram (ECG) at admission or major conditions with proved
inﬂuence on copeptin elevation (e.g., end-stage renal disease,
sepsis, anaemia, and hyponatremia). The study protocol con-
forms to the ethical guidelines of the Declaration of Helsinki
and was approved by the Ethical Committee of the Medical
University of Silesia (decision no. KNW/0022/KB1/187/11).
All patients gave their written informed consent before inclu-
sion to the study. The study registration number is
ISRCTN14112941 (http://www.isrctn.com). The design of
the study, data gathering, and analysis were conducted
according to the STARD guidelines for studies of diagnostic/
prognostic accuracy.
2.2. Clinical Assessment and Diagnosis. After inclusion, each
patient underwent initial clinical examination which
included physical examination, 12-lead ECG, echocardio-
graphic examination, and standard laboratory tests. hs-TnT
and copeptin were measured at admission. hs-TnT was
afterwards measured at six hours and repeated according to
clinical indications. As per study design, copeptin was
double-blinded until ﬁnal adjudication of the diagnosis.
hs-TnT was measured routinely in clinical care according
to current ESC guidelines for management of patients with
ACS and was recorded as such for analysis.
Initial diagnosis was set by the emergency physician
and was veriﬁed by a supervisor cardiologist based on
available data and the ESC guidelines [14]. Further, all
included patients underwent routine diagnostic and thera-
peutic procedures as indicated in the ESC guidelines for
non-ST-segment elevation ACS [14] and according to the
study design [9].
Final diagnosis of non-ST-elevation myocardial infarc-
tion (NSTEMI), unstable angina (UA), or other causes of
chest pain was based on independent opinions of two cardi-
ologists, after analysis of all available data and tests gathered
during the hospital stay. In case of incoherence of their diag-
nosis, the opinion of a third cardiologist was conclusive.
2.3. Investigational Laboratory Measurements. Copeptin was
measured once, at admission, in plasma from the blood
sample collected to tubes containing potassium ethylenedi-
aminetetraacetic acid (EDTA) managed according to the
instructions of the manufacturer of the test using the
BRAHMS Copeptin KRYPTOR kit on BRAHMS KRYPTOR
compact plus analyser (BRAHMS GmbH, Hennigsdorf,
Germany)—detection limit 4.8–500 pmol/l, 20% coeﬃcient
of variation (CV) at 12 pmol/l, and the 97.5th percentile for
healthy population 17.4 pmol/l. According to the general
rule for the optimal cutoﬀ for a marker at the 99th percentile
of healthy population, copeptin was regarded as positive
when ≥17.4 pmol/l, following available information pro-
vided by the manufacturer on the most compliant value
(97.5th percentile) to that recommended in the guidelines
[14, 18]. Rule-out zone for copeptin was deﬁned accordingly
at less than 17.4 pmol/l.
Cardiac troponin T was measured at admission, after
six hours, and at further time points according to discre-
tion of the treating physician, in plasma from a blood
sample collected to tubes containing EDTA, with a high-
sensitive assay (Elecsys Troponin T hs STAT kit on cobas
e 411 analyser, Roche Diagnostics GmbH, Mannheim,
Germany) with high-sensitive electrochemiluminescence
method (limit of detection 3–10000 ng/l, 99th percentile
for healthy population 14 ng/l (95% CI 12.7–24.9 ng/l),
and 10% CV of 13 ng/l). hs-TnT rule-out zone was deﬁned
as less than 14ng/l, according to the manufacturer indica-
tions and current guidelines [14].
2.4. The Modiﬁed HEART Score. The mHS was assessed in all
patients based on data collected at admission. As previously
described [19, 20], the score included the following variables:
age, ECG pattern, risk factors, and clinical presentation. The
HEART score originally included multiplication of upper
limit of standard cardiac troponin as one of the variables,
whereas the idea of the mHS is to combine clinical character-
istics used previously with current biomarker algorithms and
high-sensitive assays.
Each element of the mHS was assigned 0–2 points
according to the type or severity of corresponding risk
(Table 1). Patients were considered low-risk for adverse
events if the mHS was less than or equal to 3, as previously
recommended [12, 13, 21].
2.5. Endpoints. Per study design, follow-up was carried on at
30 days and one year in a phone call with the patient, rela-
tives, or primary care physician. At one year, during a visit
in the outpatient unit, the following data were gathered:
CCS and NYHA class, the occurrence of endpoints (major
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adverse cardiac events/MACE/composed of death, nonfatal
acute myocardial infarction/AMI/UA, repeated revascular-
ization, and stroke), echocardiogram with the assessment
of left ventricular ejection fraction, and blood draw for
N-terminal pro-B-type natriuretic peptide (NT-proBNP).
For current analysis, primary diagnostic endpoint was
the diagnosis of AMI. Primary prognostic endpoint was
deﬁned as death of cardiovascular origin and/or AMI within
30 days from admission. Secondary prognostic analysis was
performed at one year.
2.6. Statistical Analysis. Data were checked for normality of
distribution with Shapiro-Wilk test. Continuous variables
are presented as mean (standard deviation (SD)) or median
(interquartile range (IQR)) and were compared with Student
t-test or Mann-Whitney test, depending on the distribution.
Categorical variables are presented as n, %, and were com-
pared with chi-square test. Diagnostic and prognostic value
was assessed for three rule-out algorithms: (1) single baseline
hs-TnT concentration< 14 ng/l, (2) baseline hs-TnT concen-
tration< 14 ng/l and the mHS≤ 3, and (3) baseline hs-TnT
concentration< 14 ng/l, the mHS≤ 3, and baseline copeptin
concentration< 17.4 pmol/l. Safety of the algorithms was
assessed with sensitivity and negative predictive value
(NPV); clinical accuracy of the algorithms was deﬁned as
the proportion of true rule-out and rule-in rates. Kaplan-
Meier curves for all three algorithms were used to depict
event-free survival at 30 days. The inﬂuence of biomarkers
and the mHS on the occurrence of endpoints was calculated
in Cox proportional hazard regression model. Statistics were
performed with IBM SPSS Statistics version 22.0 (SPSS Inc.,
Chicago, IL) and GraphPad Prism, version 6.00 (GraphPad,
La Jolla, California, USA).
3. Results
3.1. General Characteristics of Patients. From December 2011
to December 2013, a total of 1665 patients presenting to the
emergency department were screened. Of them, 154 patients
met the inclusion criteria and entered the analysis. The major
reason for exclusion was late presentation, more than 6 hours
from the beginning of chest pain, characteristic for the ter-
tiary proﬁle of enrolling center, and was observed in 995
patients (60%) (Figure 1).
Overall, AMI was diagnosed in 105 patients (68%) and
UA in 30 patients (20%).
Patients were admitted with median delay of 4.1 hours
from the onset of chest pain. Baseline proﬁle was similar
irrespective of the diagnosis of AMI (Table 2). Patients ﬁnally
diagnosed with AMI had statistically higher baseline concen-
trations of hs-TnT (p < 0 001) and copeptin (p = 0 004) than
other patients. There was no diﬀerence in GFR among the
groups (p = 0 146). Statistically signiﬁcant diﬀerence was
found for admission ECG, which showed more frequent left
Table 1: Composition of the modiﬁed HEART score.
Age Electrocardiogram Risk factors∗ Clinical presentation† Points
≥65 years ST segment depression/elevation ≥3 risk factors or history of CAD∗∗ High suspicion (3/3 criteria) 2
45–64 years LBBB and LVH 1 or 2 risk factors Moderate suspicion (2/3 criteria) 1
<45 years Nonspeciﬁc changes No risk factors Low suspicion (0–1/3 criteria) 0
CAD: coronary artery disease; LBBB: left bundle branch block; LVH: left ventricular hypertrophy. ∗Considered risk factors: hypertension, diabetes mellitus, and
smoking history. ∗∗History of coronary artery disease included the history of myocardial infarction, cardiac revascularization, or former diagnosis of coronary
artery disease. †Considered criteria: type of chest pain claimed as pressure, aggravation of chest painwith physical activity, and radiation to arms and/or shoulders.
Patients
screened
n = 1665
Patients
enrolled
n = 154
hs-TnT
rule-out algorithm
n = 41
hs-TnT and mHS
rule-out algorithm
n = 18
hs-TnT, mHS
and copeptin
rule-out algorithm
n = 13
Patients excluded
STEMI
Anaemia
Hyponatremia
CPO>6h/CPD<5min
Laboratory errors
Withdrawal of IC
n = 424
n = 40
n = 31
n = 995
n = 13
n = 8
Figure 1: Study chart. STEMI: ST-segment elevation myocardial
infarction; CPO: chest pain onset; CPD: chest pain duration; IC:
informed consent; hs-TnT: high-sensitivity troponin T; mHS:
modiﬁed HEART score.
Table 2: Baseline characteristics.
All patients
n = 154
AMI
n = 105
No AMI
n = 49
Age (years) 63 (57–73) 63 (57–73) 61 (55–71)
Female sex 54, 35% 32, 30% 22, 45%
Time since the onset
of chest pain (hours)
4.1 (3.0–5.9) 4.2 (2.8–5.7) 4.1 (3.0–6.0)
hs-TnT (ng/l) 33 (13–143) 80 (31–210) 9.1 (6.7–14)
Copeptin (pmol/l) 12 (5.7–21) 14 (6.4–27) 9.0 (4.0–14)
GFR (ml/min) 92 (76–110) 90 (70–108) 95 (80–113)
ECG pattern
ST deviation 95, 62% 70, 67% 25, 51%
LBBB 10, 6.5% 10, 9.5% 0, 0%
LVH 14, 9.1% 11, 10% 3, 6%
Risk factors
Hypertension 114, 74% 84, 80% 30, 61%
Diabetes 42, 27% 33, 31% 9, 18%
Smoking 82, 53% 60, 57% 22, 45%
History of CAD∗ 67, 44% 43, 41% 24, 49%
Data are presented as median (25th–75th percentile) or n, %. AMI: acute
myocardial infarction; LBBB: left bundle branch block; LVH: left
ventricular hypertrophy; CAD: coronary artery disease. ∗History of CAD
included the history of myocardial infarction, cardiac revascularization, or
former diagnosis of coronary artery disease.
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bundle branch block in patients in whom AMI was diag-
nosed than in other patients (Table 2).
3.2. The Modiﬁed HEART Score. There were 44/154 patients
(29%) classiﬁed as low-risk according to the mHS. The
majority of patients were middle-aged, of moderate risk pro-
ﬁle, low clinical suspicion of acute coronary syndrome, and
with ST segment deviations on ECG. The distribution of
the components of the mHS in the studied population is pre-
sented in Table 3.
3.3. Diagnostic Accuracy. In the studied population, the diag-
nosis of AMI was set in 68% of patients (105/154). The com-
bination of hs-TnT, copeptin, and the mHS had higher
sensitivity and NPV than hs-TnT alone (100%, 95% CI
96.6–100, and 100%, 95% CI 75.3–100, vs. 99.3%, 95% CI
88–97.9, and 85.4%, 95% CI 70.8–94.4, respectively) and
higher than the combination of hs-TnT and the mHS
(99.1%, 95% CI 94.8–100, and 94.4%, 95% CI 72.2–99.9)
(Table 4). The accuracy of hs-TnT was 87%, hs-TnT with
mHS 78%, and hs-TnT with copeptin and mHS 77%
(Table 4).
3.4. Prognostic Accuracy.Overall, within 30 days from admis-
sion, the incidence of AMI and/or death of cardiovascular ori-
gin (including indexed AMI) was 69% (106/154 patients).
Among patients ruled out by all three algorithms, event-free
survival in patients stratiﬁed with single hs-TnT algorithm
was 85% (35/41patients) and increased after additional
use of the mHS (17/18 patients, 94%). The highest
event-free survival was observed in patients stratiﬁed with
hs-TnT, mHS, and copeptin algorithms (13/13 patients,
100%).
The lowest safety of rule out was observed for the algo-
rithm of single hs-TnT (sensitivity 94.3%, 95% CI 88.1–97.9;
NPV 85.4%, 95% CI 70.8–94.4) which was increased with
additional use of mHS (sensitivity 99.1%, 95% CI 94.9–100;
NPV 94.4%, 95% CI 72.7–99.9) and further with additional
use of copeptin (sensitivity 100%, 95% CI 96.6–100; NPV
100%, 95% CI 75.3–100) (Table 4). Increasing prognostic
safety of the algorithms was achieved at the expense of
accuracy (88%, 79%, and 77%, respectively, Table 4).
Similar results were observed at one-year follow-up,
completed in 147/154 (95%) patients. All three algorithms
had lower accuracy than at 30 days. Safety of single hs-TnT
was lower than that observed at 30 days and lower than that
of hs-TnT/mHS and hs-TnT/mHS/copeptin (Table 4).
4. Discussion
According to current practice guidelines, it is highly recom-
mended to assess prognosis in patients suspected for acute
coronary syndrome [14]. Estimation of the probability of
the development of adverse events in the short term after
admission is crucial in regard to triage, diagnostic, and
therapeutic decisions. Biomarker-based algorithms have a
well-established role in this setting [1, 8, 14, 22]; however,
high safety is achieved with serial sampling. Considering
the constant need to shorten the time to diagnosis, several
clinical scores, e.g., the modiﬁed HEART score, are under
debate. This study is the ﬁrst to evaluate safety of a strategy
with single admission hs-TnT and copeptin sampling and
the mHS in short-term prediction of adverse events in
patients presenting with chest pain.
This study shows, as the major ﬁnding, that the algorithm
combining admission concentration of hs-TnT and copeptin
with the mHS is highly eﬀective in estimation of short-term
prognosis. High safety of ruling out adverse events within
30 days from admission (sensitivity 100%, NPV 100%) might
enable early discharge of a subpopulation of patients who
would undergo standard serial measurement. This approach
might decrease the group who would undergo extended diag-
nostic process rather than be released home. The safety of the
admission hs-TnT/mHS/copeptin algorithm was higher than
that of single admission hs-TnT algorithm (5.7% diﬀerence
in NVP and 14.6% diﬀerence in sensitivity) and the admis-
sion hs-TnT/mHS algorithm (0.9% diﬀerence in NVP and
5.6% diﬀerence in sensitivity). Of note, decisive information
coming from the algorithm is available as soon as after the
ﬁrst blood sampling, before routine serial measurement.
However, one should consider relatively small diﬀerences in
NVP and sensitivity between the three algorithms. Thus,
clinical relevance of the diﬀerence between hs-TnT/mHS
and hs-TnT/mHS/copeptin should be interpreted with cau-
tion and might not justify the cost of a new laboratory test.
Standard cardiac troponin assays lacked suﬃcient safety
when used alone. Copeptin and the HEART score improved
markedly the evaluation of patients in combination with
Table 3: Modiﬁed HEART score: distribution of the components.
Characteristic Outcome
Age
≥65 years 68; 44%
45–64 years 81; 53%
<45 years 5; 3%
Electrocardiogram
ST depression/elevation 95; 62%
LBBB and LVH 14; 9%
Nonspeciﬁc changes 45; 29%
Risk factors∗
≥3 risk factors or history of CAD∗∗ 18; 12%
1 or 2 risk factors 121; 79%
No risk factors 15; 10%
Clinical presentation†
High suspicion (3/3 criteria) 4; 2%
Moderate suspicion (2/3 criteria) 41; 27%
Low suspicion (0–1/3 criteria) 109; 71%
Data are presented as n; %. LBBB: left bundle branch block; LVH: left
ventricular hypertrophy; CAD: coronary artery disease. ∗Considered risk
factors: hypertension, diabetes mellitus, and smoking history. ∗∗History of
CAD included the history of myocardial infarction, cardiac revascularization,
or former diagnosis of coronary artery disease. †Considered criteria: type of
chest pain claimed as pressure, aggravation of chest pain with physical
activity, and radiation to arms and/or shoulders.
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standard cardiac troponin by increasing prognostic value and
leading to safe reduction in additional testing in emergency
rooms [5, 23]. Introduction of high-sensitivity assays
increased the diagnostic and prognostic value of cardiac tro-
ponin, decreasing the need for and simultaneously limiting
the possibility of additional estimates for further improve-
ment. This high level of safety was achieved at the expense
of serial sampling which automatically prolonged the time
spent to reach ﬁnal decision. Single baseline hs-TnT concen-
tration was postulated as a tool for diagnostic and prognostic
purposes [6], but the accuracy of such approach was still sub-
optimal. To further shorten time to decision and maintain
high safety presented by serial measurements, combined
use of additional variables is being reassessed. According to
recent studies, the use of baseline hs-Tn concentration below
the limit of detection (LOD) and the mHS improved accu-
racy for short-term prognosis when compared to the score
or troponin alone [24]. Even though lower than hs-TnT/
mHS/copeptin, the hs-TnT/mHS algorithm still remains of
better sensitivity/NPV than hs-TnT alone, thus reinforcing
the interest for the mHS. Copeptin has an advantage over
hs-TnT for long-term risk stratiﬁcation [22] but has not been
analysed neither with mHS nor hs-Tn for short-term risk.
Combination of hs-TnT, copeptin, and the mHS, which
represent diﬀerent pathophysiological axes and carry com-
plementary information on the origin and the character of
chest pain and possible myocardial ischemia, results in an
algorithm of excellent prognostic performance. As an eﬀect,
we get a tool for rapid and ﬁrm rule out with high safety,
comparable to that achieved after serial hs-Tn sampling,
but in shorter time. Thus, the need for further serial measure-
ments is eliminated in the subgroup of ruled-out patients,
who would be possibly ruled out also with one of the recom-
mended currently serial hs-Tn protocols. Observed drop in
accuracy for the studied algorithm compared to single
hs-TnT algorithm (9% after adding the mHS to hs-TnT
Table 4: Performance of baseline combination of hs-TnT, copeptin, and the mHS for the diagnosis of AMI and short-term prognosis.
(a)
Diagnosis of AMI
hs-TnT∗ hs-TnT∗with mHS∗∗ hs-TnT∗ with copeptin† and mHS∗∗
Sensitivity 99.3% 99.1% 100%
95% CI (%) 88–97.9 94.8–100 96.6–100
NPV 85.4% 94.4% 100%
95% CI (%) 70.8–94.4 72.2–99.9 75.3–100
Test accuracy 134/154 (87%) 121/154 (78%) 118/154 (77%)
p value <0.001 <0.001 <0.001
(b)
AMI/death at 30 days
hs-TnT∗ hs-TnT∗ with mHS∗∗ hs-TnT∗ with copeptin† and mHS∗∗
Sensitivity 94.3% 99.1% 100%
95% CI (%) 88.1–97.9 94.9–100 96.6–100
NPV 85.4% 94.4% 100%
95% CI (%) 70.8–94.4 72.7–99.9 75.3–100
Test accuracy 135/154 (88%) 122/154 (79%) 119/154 (77%)
p value <0.001 <0.001 <0.001
(c)
AMI/death at one year
hs-TnT∗ hs-TnT∗ with mHS∗∗ hs-TnT∗ with copeptin† and mHS∗∗
Sensitivity 92.2% 99% 100%
95% CI (%) 85.1–96.6 94.7–100 96.5–100
NPV 80.5% 94.4% 100%
95% CI (%) 65.1–91.2 72.7–99.9 75.3–100
Test accuracy 127/147 (82%) 118/147 (80%) 115/147 (75%)
p value <0.001 <0.001 <0.001
Data are presented as median (25th–75th percentile) or n (%). hs-TnT: high-sensitivity troponin T; mHS: modiﬁed HEART score; AMI: acute myocardial
infarction; CI: conﬁdence interval; NPV: negative predictive value. ∗Baseline hs-TnT rule out at 14 ng/l. ∗∗mHS rule out at ≤3. †Baseline copeptin rule out
at 17.4 pmol/l.
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and further 2% after adding copeptin) would have little
clinical relevance if the proposed rule-out algorithm was con-
sidered as a screening for inclusion for serial sampling rather
than a substitute, so that patients not rule out at baseline with
proposed algorithm would be qualiﬁed for current standard
of care and undergo serial sampling.
A great advantage of the algorithm is, ﬁrst, the avail-
ability of all data at baseline and, second, the ease of assess-
ment and interpretation by involving well-known variables
with ﬁrm clinical experience in the interpretation of all of
them alone.
Further studies comparing the hs-TnT/mHS/copeptin
algorithm with currently recommended short diagnostic pro-
tocols with serial measurements of hs-TnT are needed before
wider clinical application of the proposed algorithm.
In conclusion, the combination of baseline hs-TnT,
copeptin, and the mHS has an excellent sensitivity and
NPV for short-term risk stratiﬁcation. Considering an ines-
capable concomitant decrease in eﬃcacy, it should be imple-
mented carefully, but such approach might improve the
triage system in emergency departments and be a bridge for
inclusion to serial blood sampling algorithms.
5. Limitations
The presented study was a secondary analysis of the
COPACS study, designed to assess the diagnostic and prog-
nostic role of copeptin in patients presenting to the ED with
chest pain and share the limitation of the COPACS study
[9, 22]. A priori established inclusion and exclusion criteria
as such might bias the results. First, the small study sample
of patients presenting with chest pain with high percentage
of diagnosed AMI might aﬀect internal as well as external
validity of the study and clinical application of the results.
Thus, conclusions should be interpreted accordingly. Second,
the time from the onset of chest pain to blood draw for ana-
lysed biomarkers in the current analysis might diﬀer from
that observed in clinical practice, resulting in possible diﬀer-
ences in sensitivity of tested algorithms. Further, the results
cannot be interpolated to other troponin or copeptin assays
and similar analysis with the use of diﬀerent assays should
be conducted to obtain more evidence on possible practical
utility of the proposed algorithm.
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